New Brunswick Government Introduces Biosimilars Switch Policy to Improve Patient Access to Safe and Effective Medicine

Shots:

New Brunswick joins British Columbia and Alberta in implementing a “switch” policy that changes coverage for specific biologic medicines
Patients switching from reference biologics to biosimilar versions will continue receiving safe, effective treatment and will enable to save millions of dollars once implemented
Sandoz is committed to supporting patients, their HCPs, and the New Brunswick Government with high quality biosimilar medicines and experienced, comprehensive patient support programs

Click here to read full press release/ article | Ref: Sandoz | Image: Sandoz